June 10, 2019
Slower walking pace linked to a higher likelihood of death and hospital visits; Researchers say gait speed should be used along with other vital signs to […]
March 27, 2019
by Scott Sanders (guest author) A cancer diagnosis is devastating but it isn’t a death sentence (in most cases). Myeloproliferative Neoplasms, MPNs, are treatable and with […]
March 14, 2019
Nationwide Population-based survey in Denmark Objective: We sought to determine the prevalence and severity of anxiety and depression among patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) and […]
February 1, 2019
Dr. Verstovsek on Benefit of Ruxolitinib Treatment in PV Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at […]
December 21, 2018
by David Wallace MPN Cancer Connection is very pleased to announce a new partnership with the PAN Foundation. Myeloproliferative Neoplasm (MPN) patients may be eligible for […]
August 7, 2018
The largest ever study of its type is the first to definitively show an increased risk of blood cancers in relatives of patients. A team […]
July 16, 2018
Brilliant work by Nathalie Cook lobbying the Australian Government for access to affordable drugs for Cancer Patients Inspiring, tenacious and rewarding work that will benefit the […]
April 9, 2018
Publisher’s Note: My source at the American Society of Hematology (ASH) informed me that “initially MPNs aren’t going to be a primary focus, however, we expect […]
March 9, 2018
Metformin demonstrates antileukemic activity and may have clinical implications for the treatment of myeloproliferative neoplasms (MPN) in combination with ruxolitinib, according to a study published in Cell Death & […]
February 22, 2018
AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system. Their […]
February 1, 2018
Imago BioSciences, a clinical-stage pharmaceutical company developing novel therapies for hematological and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted their […]
January 8, 2018
Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for […]
December 27, 2017
The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV). Data […]
December 1, 2017
A Few Simple Criteria If your doc has never been to the ASH (American Society of Hematology) conference, the largest hematology convention in the world and […]
June 29, 2017
This abstract is provided by Mads Emil Bjorn & Hans Carl Hasselbalch – Department of Hematology, Region Zealand, Roskilde, Denmark Abstract Introduction: The therapeutic landscape of […]
June 15, 2017
UT (University of Texas) San Antonio makes Dr. Ruben Mesa head of their Cancer Center Dr Ruben Mesa, one of the leading MPN Specialist in the […]
June 5, 2017
Abstract Myeloproliferative neoplasm cells recruit Gli1 positive mesenchymal stromal cells to transdifferentiate into fibrosis-causing myofibroblasts, a process that can be inhibited by a Gli inhibitor. Bone […]
April 28, 2017
Understanding Polycythemia Vera (PV), A Rare Blood Cancer Behind the Mystery, Polycythemia Vera Every year, millions of patients, families and caregivers are impacted by cancer in […]
January 29, 2017
A Solid Summary on the Latest MPN Research in 2017 Drs. Joseph R. Mikhael and Ruben A. Mesa analyze and discuss pertinent clinical studies and late […]
January 2, 2017
Long Term Exposure to Radiation puts you at higher risk for MPN The Savannah River Site is on a list of qualified places for Special Exposure […]
December 21, 2016
A survey is being conducted to learn more about the most common symptoms experienced by ET patients, and how these symptoms affect the lives of patients. […]
October 18, 2016
New Leukemia Research in Phase I/IIa Clinical Trial Biosight, an Israeli pharmaceutical development company that is working on a cure for leukemia, this week closed an […]
September 21, 2016
“Researchers found that the mean hemoglobin and hematocrit levels of the polycythemia vera group were 16.7 g/dL and 50.4%, respectively, vs 13.4 g/dL and 40.3% in […]
September 20, 2016
Key points The novel IFNα-2b AOP2014 administered once every two weeks (or once a month) has low toxicity and induces high and sustained response rates in […]
August 30, 2016
THE STORY OF JAK2 Four teams race to find the mysterious cause of a group of blood cancers. Click the link below for the complete article…
August 28, 2016
J Korean Med Sci. 2016 Oct;31(10):1579-1585. English. Published online Jul 22, 2016. http://dx.doi.org/10.3346/jkms.2016.31.10.1579 © 2016 The Korean Academy of Medical Sciences. Incidence, Survival and Prevalence Statistics of […]
August 17, 2016
Scientists in China are about to become the first to use the game-changing gene-editing technology Crispr-Cas9 on humans. Last week, Nature reported that researchers at Sichuan […]
August 16, 2016
Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects. Blood stem […]
August 15, 2016
Conclusions: MPN patients are understudied and there are currently no studies that have explored the effects of physical activity on sympton burden and QoL in these […]
August 13, 2016
T cell Therapy shows promise fighting Blood Cancers Riddell’s preliminary findings on the success of T cell therapy to cure previously terminal cases of cancer made […]
August 5, 2016
This video is outstanding, well worth watching! Dr Silver and Dr Gisslinger in Europe have been using interferon successfully for 30 years. It would be my […]
April 1, 2016
Learning about a cancer diagnosis can be an incredibly overwhelming experience, but it’s what you do afterwards that can make all the difference for the road […]
